Table 2 Summary of safety data
n (%) | Ezetimibe (N = 42) | Statin (N = 41) |
|---|---|---|
Number of adverse events | 18 (43) | 16 (39) |
≥1 adverse event | 9 (21) | 8 (20) |
Serious adverse events | 1 (2) | 0 (0) |
Serious drug-related adverse events | 0 (0) | 0 (0) |
Deaths | 0 (0) | 0 (0) |
n (%) | Ezetimibe (N = 42) | Statin (N = 41) |
|---|---|---|
Number of adverse events | 18 (43) | 16 (39) |
≥1 adverse event | 9 (21) | 8 (20) |
Serious adverse events | 1 (2) | 0 (0) |
Serious drug-related adverse events | 0 (0) | 0 (0) |
Deaths | 0 (0) | 0 (0) |